Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.


Player Avatar pchop123 (80.25) Submitted: 9/6/2012 10:32:34 AM : Underperform Start Price: $41.30 DVAX Score: -6.78

may be running out of upside whil while waiting for next approval

Featured Broker Partners